

New Product Approvals for Zydus Cadila from USFDA

Ahmedabad, 15 May 2008

Zydus Cadila has received four product approvals from the USFDA. The group has received approvals to market Pravastatin Sodium Tablets USP 10, 20, 40 and 80 mg and tentative approvals for Escitalopram Oxalate Tablets, 5,10 and 20 mg, Losartan Potassium and Hydrochlorthiazide Tablets 50 mg/12.5 mg and 100 mg/25 mg and Anastrozole Tablets 1 mg.

The US market of Pravastatin Sodium Tablets, a lipid lowering agent which falls in the cardiovascular segment, was estimated at USD 1.9 billion in 2007, while the branded sales of Escitalopram Oxalate Tablets, an anti-depressant, was estimated at USD 3 billion. Losartan Potassium and Hydrochlorthiazide Tablets, an anti-hypertensive, was estimated at USD 785 million and that of Anastrozole Tablets, a hormone therapy to treat breast cancer, was estimated at USD 813 million in 2007 as per NDC.

###